Assaf P. Oron

Assaf P. Oron

Auto-generated profile, based on publicly available information

Assaf P. Oron

Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
CKCliff Kerr
Cliff Kerr
RSRobyn M. Stuart
Robyn M. Stuart
DMDina Mistry
Dina Mistry
RARomesh Abeysuriya
Romesh Abeysuriya
KRKatherine Rosenfeld
Katherine Rosenfeld
DKDaniel J. Klein
Daniel J. Klein
The COVID-19 pandemic has created an urgent need for models that can project epidemic trends, explore intervention scenarios, and estimate resource needs. Here we describe the methodology of Covasim (COVID-19 Agent-based Simulator), an open-source model developed to help address these questions. Covasim includes country-specific demographic information on age structure and population size; realistic transmission networks in different social layers, including households, schools, workplaces, long-term care facilities, and communities; age-specific disease outcomes; and intrahost viral dynamics, including viral-load-based transmissibility. Covasim also supports an extensive set of interventions, including non-pharmaceutical interventions, such as physical distancing and protective equipment; pharmaceutical interventions, including vaccination; and testing interventions, such as symptomatic and asymptomatic testing, isolation, contact tracing, and quarantine. These interventions can incorporate the effects of delays, loss-to-follow-up, micro-targeting, and other factors. Implemented in pure Python, Covasim has been designed with equal emphasis on performance, ease of use, and flexibility: realistic and highly customized scenarios can be run on a standard laptop in under a minute. In collaboration with local health agencies and policymakers, Covasim has already been applied to examine epidemic dynamics and inform policy decisions in more than a dozen countries in Africa, Asia-Pacific, Europe, and North America.

13 July 2022 in Anesthesiology
Verified
Journal Article
Closed access
PDF file
AOAssaf P. Oron
Assaf P. Oron
MSM.B. Michael J. Souter
M.B. Michael J. Souter
NFNancy Flournoy
Nancy Flournoy
Summary: For the task of estimating a target benchmark dose such as the ED50 (the dose that would be effective for half the population), an adaptive dose-finding design is more effective than the standard approach of treating equal numbers of patients at a set of equally spaced doses. Up-and-down is the most popular family of dose-finding designs and is in common use in anesthesiology. Despite its widespread use, many aspects of up-and-down are not well known, implementation is often misguided, and standard, up-to-date reference material about the design is very limited. This article provides an overview of up-and-down properties, recent methodologic developments, and practical recommendations, illustrated with the help of simulated examples. Additional reference material is offered in the Supplemental Digital Content.

23 January 2013 in Clinical Trials
Verified
Journal Article
Open access
PDF file
AOAssaf P Oron
Assaf P Oron
PHPeter D Hoff
Peter D Hoff
Background: Novel dose-finding designs for Phase I cancer clinical trials, using estimation to assign the best estimated Maximum Tolerated Dose (MTD) at each point in the experiment, most prominently via Bayesian techniques, have been widely discussed and promoted since 1990. Purpose: To examine the small-sample behavior of these ‘Bayesian Phase I’ designs, and also of non-Bayesian designs sharing the same main ‘Long-Memory’ traits of using likelihood estimation and assigning the estimated MTD to the next patient. Methods: Data from several recently published experiments are presented and discussed, and Long-Memory designs’ operating principles are explained. Simulation studies compare the small-sample behavior of Long-Memory designs with short-memory ‘Up-and-Down’ designs. Results: In simulation, Long-Memory and Up-and-Down designs achieved similar success rates in finding the MTD. However, for all Long-Memory designs examined, the number n* of cohorts treated at the true MTD was highly variable between simulated experiments drawn from the same toxicity-threshold distribution. Further investigation using the same set of thresholds in permuted order indicates that this Long-Memory behavior is driven by sensitivity to the order in which participants enter the experiment. This sensitivity is related to Long-Memory designs’ ‘winner-takes-all’ dose-assignment rule, which grants the early cohorts a disproportionately large influence, and causes many experiments to settle early on a specific dose. Additionally for the Bayesian Long-Memory designs, the prior-predictive distribution over the dose levels has a substantial impact upon MTD-finding performance, long into the experiment. Limitations: While the numerical evidence for Long-Memory designs’ order sensitivity is broad, and plausible explanations for it are provided, we do not present a theoretical proof of the phenomenon. Conclusions: Method developers, analysts, and practitioners should be aware of Long-Memory designs’ order sensitivity and related phenomena. In particular, they should be informed that settling on a single dose does not guarantee that this dose is the MTD. Presently, Up-and-Down designs offer a simpler and more robust alternative for the sample sizes of 10–40 patients used in most Phase I trials. Future designs might benefit from combining the two approaches. We also suggest that the field’s paradigm change from dose-selection to dose-estimation.


12 September 2022 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
NNNavideh Noori
Navideh Noori
LSLaura Skrip
Laura Skrip
AOAssaf P. Oron
Assaf P. Oron
KMKevin A. McCarthy
Kevin A. McCarthy
JPJosh L. Proctor
Josh L. Proctor
Indi TrehanIndi Trehan
Indi Trehan
: The bidirectional interaction between undernutrition and infection can be devastating to child health. Nutritional deficiencies impair immunity and increase susceptibility to infection. Simultaneously, infections compound undernutrition by increasing metabolic demand and impairing nutrient absorption. Treatment of acute malnutrition (wasting) can reverse some of its deleterious effects and reduce susceptibility to infectious diseases. Nutrition-specific approaches may be packaged with other interventions, including immunization, to support overall child health. To understand how mass nutritional supplementation, treatment of wasting, and vaccination affect the dynamics of a vaccine-preventable infection, we developed a population-level, compartmental model of measles transmission stratified by age and nutrition status. We simulated a range of scenarios to assess the potential reductions in measles infection and mortality associated with targeted therapeutic feeding for children who are wasted and with a mass supplementation intervention. Nutrition interventions were assumed to increase engagement with the health sector, leading to increased vaccination rates. We found that the combination of wasting treatment and mass supplementation coverage followed by an increase in vaccination coverage of non-wasted children from a baseline of 75% to 85%, leads to 34% to 57% and 65% to 77% reduction in measles infection and mortality and 56% to 60% reduction in overall mortality among wasted children, compared with the wasting treatment alone. Our work highlights the synergistic benefits that may be achieved by leveraging mass nutritional supplementation as a touch point with the health system to increase rates of vaccination and improve child survival beyond what would be expected from the additive benefits of each intervention.

1 August 2019 in Journal of Applied Statistics
Verified
Journal Article
Closed access
NFNancy Flournoy
Nancy Flournoy
AOAssaf P. Oron
Assaf P. Oron
There is a long literature on bias in maximum likelihood estimators. Here we demonstrate that adaptive dose-finding procedures (such as Continual Reassessment Methods, Up-and-Down and Interval Designs) themselves induce bias. In particular, with Bernoulli responses and dose assignments that depend on prior responses, we provide an explicit formula for the bias of observed response rates. We illustrate the patterns of bias for designs that aim to concentrate dose allocations around a target dose, which represents a specific quantile of a cumulative response-threshold distribution. For such designs, bias tends to be positive above the target dose and negative below it. To our knowledge, this property of dose-finding designs has not previously been recognized by design developers. We discuss the implications of this bias and suggest a simple shrinkage mitigation formula that improves estimation at doses away from the target.